Core Viewpoint - Spring Medical has shown significant stock performance, with a year-to-date increase of 73.18%, outperforming the Hang Seng Index by 27.31% [2] Financial Performance - As of March 31, 2025, Spring Medical reported total revenue of 230 million yuan, a year-on-year increase of 3.6% - The net profit attributable to shareholders was 58.071 million yuan, reflecting a growth of 5.2% - The gross profit margin stood at 66.69%, while the debt-to-asset ratio was 17.11% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Spring Medical - The company's price-to-earnings (P/E) ratio is 41.21, ranking 45th in the healthcare equipment and services industry, which has an average P/E ratio of -1.39 and a median of 1.36 [3] Company Overview - Founded in 1998, Spring Medical focuses on high-end medical device development, offering a full range of orthopedic products including joint, spine, sports medicine, and trauma products - The company has 124 medical device registrations and continues to expand its product line to meet diverse market needs [3][4] Research and Development - Spring Medical boasts a multidisciplinary team with over 20 years of industry experience, including experts in mechanical design, materials science, biomechanics, and clinical medicine - The company has received multiple qualifications, including being recognized as a national high-tech enterprise and a champion enterprise in manufacturing [4] Innovation and Market Strategy - As a leading player in China's orthopedic industry, Spring Medical has filled domestic market gaps with innovative products, enhancing its core competitiveness and industry recognition - The company aims to solve key technical challenges in the industry and promote independent innovation in the joint field [5]

Group 1 - The core viewpoint of the news is the performance and holdings of the Ping An Low Carbon Economy Mixed A fund, which has shown positive growth in recent months and has a significant portion of its assets allocated to top-performing stocks [1][3]. - As of July 23, 2025, the latest net value of the Ping An Low Carbon Economy Mixed A fund is 1.0878 yuan, reflecting a growth of 1.04%. The fund has achieved a return of 5.83% over the past month, 18.07% over the past six months, and 17.20% year-to-date [1]. - The fund's top ten stock holdings account for a total of 68.78%, with notable investments in companies such as Gigabyte (9.02%), Gree Electric Appliances (8.50%), and Xpeng Motors (8.33%) [1]. Group 2 - The Ping An Low Carbon Economy Mixed A fund was established on August 10, 2020, and as of June 30, 2025, it has a total scale of 1.427 billion yuan, managed by fund manager He Jie [1]. - He Jie has a background in finance, holding a master's degree from the University of Augsburg in Germany, and has held various positions in investment management and research prior to joining Ping An Fund Management Company in August 2021 [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公告之目的為就該等年報提供補充資料。 (1) 2022年年報的補充資料 除2022年年報所載合併財務報表附註十三（三）的披露資料外，本公司謹此 提供下列有關並非董事的主要行政人員薪酬之額外資料： 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 有關2022年、2023年及2024年年報的補充公告 茲提述(1)北京市春立正達醫療器械股份有限公司（「本公司」，連同其附屬公司 統稱「本集團」）截至2022年12月31日止年度的年度報告（「2022年年報」）；(2)本 集團截至2023年12月31日止年度的年度報告（「2023年年報」）；及(3)本集團截至 2024年12月31日止年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 有關2022年、2023年及2024年年報的補充公告 除2022年年報所載合併財務報表附註十三（三）的披露資料外，本公司謹此 提供下列有關並非董事的主要行政人員薪酬之額外資料： 本公司主要行政人員（並非董事）截至2022年12月31日止年度的薪酬載列如 下： 茲提述(1)北京市春立正達醫療器械股份有限公司（「本公司」，連同其附屬公司 統稱「本集團」）截至2022年12月31日止年度的年度報告（「2022年年報」）；(2)本 集團截至2023年12月31日止年度的年度報告（「2023年年報」）；及(3)本集團截至 2024年12月3 ...

Group 1 - The core viewpoint of the articles highlights that Chunzhi Medical's stock closed at 19.35 yuan, down 3.25%, with a rolling PE ratio of 58.05 times and a total market value of 7.422 billion yuan [1] - The average PE ratio for the medical device industry is 52.34 times, with a median of 36.99 times, placing Chunzhi Medical at the 89th position in the industry ranking [1] - As of the first quarter of 2025, two institutions hold shares in Chunzhi Medical, with a total of 5.0428 million shares valued at 0.94 billion yuan [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest performance report for the first quarter of 2025 shows that the company achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, a year-on-year increase of 5.20%, with a gross profit margin of 66.69% [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1]

最新一期业绩显示，2025年一季报，公司实现营业收入2.30亿元，同比3.60%；净利润5807.11万元，同 比5.20%，销售毛利率66.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13春立医疗57.5158.832.5573.53亿行业平均 51.8747.354.50108.06亿行业中值37.4837.062.5352.67亿1九安医疗10.8510.970.85183.07亿2英科医疗 12.0913.041.08191.07亿3新华医疗14.3613.311.1792.03亿4振德医疗15.4114.530.9855.95亿5山东药玻 15.4415.491.77146.06亿6奥美医疗15.7915.481.6257.06亿7康德莱16.2616.271.3535.03亿8奥泰生物 16.8417.751.3653.69亿9九强生物16.8915.712.0783.66亿10维力医疗17.2617.942.0239.36亿11安杰思 18.0518.262.1853.58亿12安图生物19.0418.172.45217.08亿 来源：金融界 7月16日，春立医疗今日收盘19 ...

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, particularly for 2025, suggesting a potential for diverse investment opportunities as the sector recovers from low valuations and public fund allocations [10]. Core Insights - The pharmaceutical sector is currently experiencing low valuations, with public funds under-allocating to this area. The report anticipates a recovery driven by macroeconomic factors and significant product launches [10]. - The report emphasizes a shift in the innovative drug sector from quantity to quality, highlighting the importance of differentiated products and international expansion for profitability [10]. - The medical device sector is seeing a rebound in bidding volumes, particularly in imaging equipment, and is expected to benefit from domestic product upgrades and international market expansion [10]. - The report identifies a growing trend in the CXO and life sciences services sector, with expectations for increased investment and a recovery in demand [10]. - The traditional Chinese medicine sector is projected to benefit from policy changes and market dynamics, with specific companies recommended for investment based on their unique product offerings and market positions [12]. Summary by Sections Market Review - The report notes a 1.80% increase in the CITIC Pharmaceutical Index, outperforming the CSI 300 Index by 0.98 percentage points, ranking 16th among 30 sectors [7]. - The top-performing stocks include Frontline Bio-U, MediWest, and Lianhuan Pharmaceutical, while the worst performers include ST Weiming and Innovent Biologics [7]. Overall Perspective and Investment Themes - The report suggests that the pharmaceutical industry is poised for growth, with a focus on innovative drugs, medical devices, and traditional Chinese medicine. Specific companies are highlighted for their potential in these areas [10][12]. - The report also discusses the implications of policy changes and market trends for the pharmaceutical and medical device sectors, indicating a favorable environment for investment [10][12]. Company-Specific Insights - Companies like Baiyi, Xinda, and Kangfang are highlighted for their innovative drug pipelines and potential for growth in the coming years [10][12]. - The report provides detailed insights into the clinical progress of various drugs across different companies, indicating a robust pipeline that could drive future revenue [13][20][24][30][35][38].

Core Viewpoint - The controlling shareholder, Shi Chunbao, has increased his stake in Chunli Medical from 55.92% to 56.22%, triggering a 1% threshold change in equity [1][2]. Group 1: Shareholder Information - The controlling shareholder is Shi Chunbao, with an increase in shareholding from 11,904.5093 thousand shares (31.04%) to 12,020.9043 thousand shares (31.34%) [2]. - The consistent shareholder, Yue Shujun, maintained her stake at 9,544.7900 thousand shares (24.88%) [2]. - The total shareholding of both shareholders increased from 21,449.2993 thousand shares (55.92%) to 21,565.6943 thousand shares (56.22%) [2]. Group 2: Equity Change Details - The equity change occurred between May 6, 2025, and July 10, 2025, through self-funded purchases via centralized bidding [1][2]. - The increase in shareholding does not violate any prior commitments or plans made by the shareholders [1]. - The change does not trigger mandatory tender offer obligations under relevant regulations [1]. Group 3: Regulatory Compliance - The equity change does not require the disclosure of an equity change report as per the "Measures for the Administration of Acquisitions of Listed Companies" and other relevant regulations [2]. - The company will continue to monitor the situation and fulfill its information disclosure obligations as required [2].

Group 1 - The core viewpoint of the article highlights that Spring Medical has a closing price of 18.56 yuan, with a PE ratio of 55.68 times, and a total market value of 7.119 billion yuan [1] - The average PE ratio for the medical device industry is 52.06 times, with a median of 37.22 times, placing Spring Medical at the 88th position in the industry ranking [1] - As of March 31, 2025, Spring Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The company was recognized as a champion enterprise in the artificial joint prosthesis manufacturing industry by the Ministry of Industry and Information Technology in 2024 [1] - In the latest quarterly report for Q1 2025, Spring Medical achieved an operating income of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, a year-on-year increase of 5.20%, with a gross profit margin of 66.69% [1]

证券代码：688236 证券简称：春立医疗 公告编号：2025-030 北京市春立正达医疗器械股份有限公司 关于控股股东权益变动触及 1%刻度的提示性公告 控股股东史春宝先生及其一致行动人岳术俊女士保证向本公司提供的 信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息 一致。 | 信息披露义务人名称 | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | | 史春宝 | 控股股东/实控人 ☑ | | | □ | 控股股东/实控人的一致 | □ _____________ | | | 行动人 | 不适用 ☑ | | □ | 其他直接持股股东 | | 重要内容提示： 权益变动方向 比例增加☑ 比例减少□ 权益变动前合计比例 55.92% 权益变动后合计比例 56.22% 本次变动是否违反已作出的承 诺、意向、计划 是□ 否☑ 是否触发强制要约收购义务 是□ 否☑ 二、 权益变动触及 1%刻度的基本情况 公司于 2025 年 7 月 10 日收到公司控股股东史春宝先生发来的《关于权益 变动比例触及 1%整数倍的告知函》， ...